NASDAQ:KRRO Korro Bio Q1 2025 Earnings Report $11.94 -0.75 (-5.91%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$12.15 +0.21 (+1.75%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Korro Bio EPS ResultsActual EPS-$2.49Consensus EPS -$2.60Beat/MissBeat by +$0.11One Year Ago EPSN/AKorro Bio Revenue ResultsActual Revenue$2.55 millionExpected Revenue$0.13 millionBeat/MissBeat by +$2.42 millionYoY Revenue GrowthN/AKorro Bio Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time4:00PM ETUpcoming EarningsKorro Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Korro Bio Earnings HeadlinesKorro to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)May 14, 2025 | theglobeandmail.comHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.June 26 at 2:00 AM | Timothy Sykes (Ad)Korro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSee More Korro Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email. Email Address About Korro BioKorro Bio (NASDAQ:KRRO), a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Korro Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
